Home›Clinical trials›GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

A study of a GLP-1 medicine, semaglutide, in people with pancreatic cancer.

Who can join
Adults 18+, have pancreatic cancer, BMI 25+.
What you take
Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 2 years.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 1Sponsor University of ArizonaDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 30

What this study is for

Primary condition: Pancreatic Cancer. Also studied in: Colorectal Cancer, Hepatocellular Carcinoma.

Full scientific study title: GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer.

Who can join

Age18 to 99SexAnyBMI25 or higher

Adults 18+, have pancreatic cancer, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Histological or cytological diagnosis of pancreatic adenocarcinoma or colorectal adenocarcinoma. Previous tumor tissue testing is acceptable. Please refer to the "additional HCC cohort criteria" below.
  • The subject has disease that is not amenable to curative-intent management (e.g., oligometastatic disease)
  • Measurable disease per RECIST v1.1 as determined by the investigator
  • Patients must be appropriate candidates for first-line, SOC treatment.
  • SOC treatment as defined by NCCN® guidelines or institutional standard is allowable, however, options restricted to:

Key exclusion criteria

  • The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) for metastatic and/or unresectable disease.
  • BMI \< 25 kg/m2
  • For colorectal cancer only - Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumors.
  • For colorectal cancer only - BRAF V600E mutant tumors.
  • A personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Where this trial runs

This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.

Arizona1 site

Timeline

Scheduled start: July 10, 2026. Expected completion: June 30, 2028. Last updated on ClinicalTrials.gov: July 2, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.